StockData
Cogent Biosciences, Inc. logo

Cogent Biosciences, Inc. (COGT) stock

COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$27.44−1.12 (-3.92%)

Close on Nov 16, 2026Market cap $4.76BP/E –Yield –

Cogent Biosciences ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Cogent Biosciences's ebitda for the twelve months ending Jun 30, 2026 was -$386.42M. For fiscal 2025 it was -$330.76M. The highest annual figure on record is -$24.98M in fiscal 2017.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$330.76M–
FY2024Dec 31, 2024-$273.44M–
FY2023Dec 31, 2023-$205.83M–
FY2022Dec 31, 2022-$147.04M–
FY2021Dec 31, 2021-$75.40M–
FY2020Dec 31, 2020-$81.48M–
FY2019Dec 31, 2019-$30.89M–
FY2018Dec 31, 2018-$34.68M–
FY2017Dec 31, 2017-$24.98M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$101.90M–
Q1 FY2026Mar 31, 2026-$102.98M–
Q4 FY2025Dec 31, 2025-$98.83M–
Q3 FY2025Sep 30, 2025-$82.71M–
Q2 FY2025Jun 30, 2025-$74.93M–
Q1 FY2025Mar 31, 2025-$74.29M–
Q4 FY2024Dec 31, 2024-$73.06M–
Q3 FY2024Sep 30, 2024-$74.79M–
Q2 FY2024Jun 30, 2024-$63.78M–
Q1 FY2024Mar 31, 2024-$61.81M–
Q4 FY2023Dec 31, 2023-$57.60M–
Q3 FY2023Sep 30, 2023-$59.00M–
Q2 FY2023Jun 30, 2023-$46.52M–
Q1 FY2023Mar 31, 2023-$42.71M–
Q4 FY2022Dec 31, 2022-$43.37M–
Q3 FY2022Sep 30, 2022-$36.57M–
Q2 FY2022Jun 30, 2022-$35.76M–
Q1 FY2022Mar 31, 2022-$31.35M–
Q4 FY2021Dec 31, 2021-$25.57M–
Q3 FY2021Sep 30, 2021-$19.77M–
Q2 FY2021Jun 30, 2021-$17.28M–
Q1 FY2021Mar 31, 2021-$12.78M–
Q4 FY2020Dec 31, 2020-$11.44M-547.9%
Q3 FY2020Sep 30, 2020-$57.08M–
Q2 FY2020Jun 30, 2020-$7.12M–
Q1 FY2020Mar 31, 2020-$5.85M–
Q4 FY2019Dec 31, 2019$2.55M–
Q3 FY2019Sep 30, 2019-$11.72M–
Q2 FY2019Jun 30, 2019-$10.21M–
Q1 FY2019Mar 31, 2019-$11.51M–
Q4 FY2018Dec 31, 2018-$8.65M–
Q3 FY2018Sep 30, 2018-$10.25M–
Q2 FY2018Jun 30, 2018-$9.11M–
Q1 FY2018Mar 31, 2018-$6.67M–
Q4 FY2017Dec 31, 2017-$6.57M–
Q3 FY2017Sep 30, 2017-$6.87M–
Q2 FY2017Jun 30, 2017-$5.75M–
Q1 FY2017Mar 31, 2017-$5.79M–

More Cogent Biosciences figures

See a number that looks wrong?